Testing of unselected ovarian cancer cases in non-Ashkenazi Jewish populations shows that the frequency of deleterious BRCA1 and BRCA2 variants ranged from 3–10% and 0.6–6%, respectively [17]. This evidence concerns the gene BRCA1 and ovarian carcinoma.